

## 研究発表

### 1 . 論文発表

研究代表者：堀内孝彦

- Furukawa M, Kiyohara C, Horiuchi T, Tsukamoto H, Mitoma H, Kimoto Y, Uchino A, Nakagawa M, Oryoji K, Shimoda T, Harada M, Akashi K: Prevalence and risk factors of vertebral fracture in Japanese females with systemic lupus erythematosus. *Mod. Rheumatol.* in press

- Ueda N, Tsukamoto H, Mitoma H, Ayano M, Tanaka A, Ohta S-I, Inoue Y, Arinobu Y, Niiro H, Akashi K, Horiuchi T: The cytotoxic effects of certolizumab pegol and golimumab mediated by transmembrane tumor necrosis factor α. *Inflamm. Bowel Dis.* in press

- Washio M, Nakano T, Kawaguchi Y, Takagi K, Kiyohara C, Tsukamoto H, Tokunaga S, Horiuchi T: Tumor necrosis factor receptor-associated periodic syndrome (TRAPS) in Japan: a review of the literature. *Mod. Rheumatol.* 23(2): 230-237, 2013

- Kusuhsara K, Hoshina T, Saito M, Ishimura M, Inoue H, Horiuchi T, Sato T, Hara T: Successful treatment of a patient with tumor necrosis factor receptor-associated periodic syndrome using a half-dose of etanercept. *Pediatr. Int.* 54(4): 552-555, 2012

- Umegaki N, Kira M, Horiuchi T, Itoi S, Tani M, Yokomi A, Tanemura A, Miyahara H, Hatanaka M, Kitamura H, Kitano E, Katayama I: Etanercept is safely used for treating psoriatic arthritis in a patient complicated with type 1 hereditary angioedema. *Mod. Rheumatol.* 22(6): 928-930, 2012

- Horiuchi T, Ohi H, Ohsawa I, Fujita T, Matsushita M, Okada N, Seya T, Yamamoto T, Endo Y, Hatanaka M, Wakamiya N, Mizuno M, Nakao M, Okada H, Tsukamoto H, Matsumoto M, Inoue N, Nonaka M, Kinoshita T: Guideline for Hereditary Angioedema (HAE) 2010 by the Japanese Association for Complement Research. *Allergol. Int.* 61(4): 539-562, 2012

- Harigai M, Tanaka Y, Maisawa S, and the JA21963 Study Group: Safety and efficacy of various dosages of ocrelizumab in Japanese patients with rheumatoid arthritis with an inadequate response to methotrexate therapy: A placebo-controlled double-blind parallel-group study. *J. Rheumatol.* 39(3): 486-495, 2012

- Miyasaka N, Hara M, Koike T, Saito E, Yamada M, Tanaka Y; GB-0998 Study Group: Effects of intravenous immunoglobulin therapy in Japanese patients with polymyositis and dermatomyositis resistant to corticosteroids: a randomized

double-blind placebo-controlled trial.  
*Mod. Rheumatol.* 22(3): 382-393, 2012

• Suematsu R, Ohta A, Matsuura E, Takahashi H, Fujii T, Horiuchi T, Minota S, Ishigatubo Y, Ota T, Takei S, Soejima S, Inoue H, Koarada S, Tada Y, Nagasawa K: Therapeutic response of patients with adult Still's disease to biologic agents; multicenter results in Japan. *Mod. Rheumatol.* 22(5): 712-719, 2012

• Kiyohara C, Horiuchi T, Takayama K, Nakanishi Y: Genetic polymorphisms involved in carcinogen metabolism and DNA repair and lung cancer risk in a Japanese population. *J. Thorac. Oncol.* 7(6): 954-962, 2012

• Kiyohara C, Washio M, Horiuchi T, Tada Y, Asami T, Ide S, Atsumi T, Kobashi G, Takahashi H, and the Kyushu Sapporo SLE (KYSS) Study Group: Cigarette smoking, alcohol consumption and the risk of systemic lupus erythematosus: a case-control study in a Japanese population. *J. Rheumatol.* 39(7): 1367-1370, 2012

• Tada Y, Suematsu E, Ueda A, Nagano S, Sawabe T, Nishizaka H, and Horiuchi T: Clinical factors to predict a poor prognosis and refractory disease in patients with polymyositis and dermatomyositis associated with

interstitial lung disease. *Clin. Exp. Rheumatol.* 30(3): 450, 2012

• Niilo H, Jabbarzadeh-Tabrizi S, Kikushige Y, Shima T, Noda K, Ota S-I, Tsuzuki H, Inoue Y, Arinobu Y, Iwasaki H, Shimoda S, Baba E, Tsukamoto H, Horiuchi T, Taniyama T, Akashi K: CIN85 is required for Cbl-mediated regulation of antigen receptor signaling in human B cells. *Blood* 119(10): 2263-2273, 2012

• Yamamoto T, Horiuchi T, Miyahara H, Yoshizawa S, Maehara J, Shono E, Takamura K, Machida H, Tsujioka K, Kaneko T, Uemura N, Suzawa K, Inagaki N, Umegaki N, Kasamatsu Y, Hara A, Arinobu Y, Inoue Y, Niilo H, Kashiwagi Y, Harashima SI, Tahira T, Tsukamoto H, Akashi K: Hereditary angioedema in Japan: Genetic analysis of 13 unrelated cases. *Am. J. Med. Sci.* 343(3): 210-214, 2012

• Harashima S-I, Horiuchi T, Wang Y, Notkins AL, Seino Y, Inagaki N: Sorting nexin 19 regulates the number of sense core vesicles in pancreatic ss-cells. *J. Diabetes Invest.* 3(1): 52-61, 2012

• Kiyohara C, Washio M, Horiuchi T, Tada Y, Asami T, Ide S, Atsumi T, Kobashi G, Takahashi H, and the Kyushu Sapporo SLE (KYSS) Study Group: Risk modification by CYP1A1 and GSTM1

polymorphisms in the association of cigarette smoking and systemic lupus erythematosus in a Japanese population. *Scand. J. Rheumatol.* 41(2): 103-109, 2012

• Okada Y, Shimane K, Kochi Y, Tahira T, Suzuki A, Higasa K, Takahashi A, Horita T, Atsumi T, Ishii T, Okamoto A, Fujio K, Hirakata M, Amano H, Kondo Y, Ito S, Takada K, Mimori A, Saito K, Kamachi M, Kawaguchi Y, Ikari K, Mohammed OW, Matsuda K, Terao C, Ohmura K, Myouzen K, Hosono N, Tsunoda T, Nishimoto N, Mimori T, Matsuda F, Tanaka Y, Sumida T, Jamanaka H, Takasaki Y, Koike T, Horiuchi T, Hayashi K, Kubo M, Kamatani N, Yamada R, Nakamura Y, Yamamoto K: A genome-wide association study identified AFF1 as a susceptibility locus for systemic lupus erythematosus in Japanese. *PLoS Genetics* 8(1): e1002455, 2012

• 上田尚靖、塚本浩、堀内孝彦: TRAPS の病態と病因. 炎症と免疫 20(3): 293-298, 2012

• 赤星光輝、堀内孝彦: Neonatal Fc 受容体阻害療法の可能性. リウマチ科 47(5) : 543-550, 2012

• Furukawa M, Kiyohara C, Tsukamoto H, Mitoma H, Kimoto Y, Uchino A, Nakagawa M, Oryoji K, Nakashima H, Akashi K, Harada M, Horiuchi T: Prevalence of and

risk factors for low bone mineral density in Japanese female patients with systemic lupus erythematosus. *Rheumatol. Int.* 31(3): 365-376, 2011

• Tsukamoto H, Nagafuji K, Horiuchi T, Mitoma H, Niilo H, Arinobu Y, Inoue Y, To K, Miyamoto T, Iwasaki H, Teshima T, Harada M, Akashi K: Analysis of immune reconstitution after autologous CD34+ stem/progenitor cell transplantation for systemic sclerosis: predominant reconstitution of Th1 CD4+ T cells. *Rheumatology(Oxford)* 50(5):944-952, 2011

• Yabuuchi H, Matsuo Y, Tsukamoto H, Sunami S, Kamitani T, Sakai S, Hatakenaka M, Nagafuji K, Horiuchi T, Harada M, Akashi K, Honda H: Correlation between pretreatment or follow-up CT findings and therapeutic effect of autologous peripheral blood stem cell transplantation for interstitial pneumonia associated with systemic sclerosis. *Eur. J. Radiol* 79(2):e74-79, 2011

• Harashima S, Wang Y, Horiuchi T, Seino Y, Inagaki N: Purkinje cell protein4 positively regulates neurite outgrowth and neurotransmitter release. *J. Neurosci. Res.* 89(10): 1519-1530, 2011

• Yoshida K, Komai K, Shiozawa K, Mashida A, Horiuchi T, Tanaka Y, Nose M, Hashiramoto A, Shiozawa S: Role of the MICA polymorphism in systemic

lupus erythematosus. *Arthritis Rheum.* 63(10): 3058-3066, 2011

• Kiyohara C, Horiuchi T, Takayama K, Nakanishi Y: Methylenetetrahydrofolate-reductase polymorphisms and interaction with smoking and alcohol consumption in lung cancer risk:a case-control study in a Japanese population. *BMC Cancer* 11: 459-468, 2011

• Kasamatsu Y, Yoshinoya K, Kasamatsu Y, Yamamoto T, Horiuchi T, Kadoma M: A case of hereditary angioedema involving recurrent abdominal attacks. *Intern. Med.* 50 (23): 2911-2914, 2011

• 堀内孝彦、原島伸一、下田照文：膜型TNFの構造と機能。リウマチ科 46(4):442-450, 2011

• 堀内孝彦：突発性浮腫への対応 - 遺伝性血管性浮腫 (HAE) の鑑別診断と治療 - .

週刊「日本医事新報」No4545,73-79,2011

• Horiuchi T, Mitoma H, Harashima S, Tsukamoto H, Shimoda T. Transmembrane TNF-alpha: structure, function and interaction with anti-TNF agents. *Rheumatology(Oxford)*49(7):1215-28, 2010

• Kimoto Y, Horiuchi T, Tsukamoto H, Kiyohara C, Mitoma H, Uchino A, Furugo I, Yoshizawa S, Ueda A, Harashima S, Sawabe T, Tahira T, Hayashi K, Yoshizawa S, Shimoda T, Akashi K, Harada M: Association of killer cell immuno globulin- like receptor 2DL5 with

systemic lupus erythematosus and accompanying infections. *Rheumatology (Oxford)* 49(7): 1346-53, 2010

• Kiyohara C, Horiuchi T, MiyakeY, Takayama K, Nakanishi Y: Cigarette smoking, TP53 Arg72Pro, TP53BP1 Asp353Glu and the risk of lung cancer in a Japanese population. *Oncol. Rep.* 23(5): 1361-8, 2010

• Kiyohara C, Horiuchi T, Takayama K, Nakanishi Y. IL1B rs1143634 polymorphism, cigarette smoking, alcohol use, and lung cancer risk in a Japanese population. *J. Thorac. Oncol* 5(3): 299-304, 2010

• Nakashima Y, Kondo M, Horiuchi T, Ishinishi T, Jojima H, Kuroda K, Miyahara H, Nagamine R, Nakashima H, Otsuka T, Saikawa I, Shono E, Suematsu E, Tsuru T, Wada K, Iwamoto Y: Clinical evaluation of tocilizumab for patients with active rheumatoid arthritis refractory to anti-TNF biologics: tocilizumab in combination with methotrexate. *Mod Rheumatol* 20(4): 343-52, 2010

• Uchino A, Tsukamoto H, Nakashima H, Yoshizawa S, Furugo I, Mitoma H, Takahashi M, Oryoji K, Yoshizawa S, Shimoda T, Niilo H, Otsuka T, Tada Y, Nagasawa K, Yano T, Nonaka T, Oishi R, Akashi K, Horiuchi T: Tacrolimus is effective for lupus nephritis patients with

*persistent proteinuria. Clin. Exp. Rheumatol* 28(1): 6-12, 2010

• Nishimoto K, Kochi Y, Ikari K, Yamamoto K, Suzuki A, Shimane K, Nakamura Y, Yano K, Iikuni N, Tsukahara S, Kamatani N, Okamoto H, Kaneko H, Kawaguchi Y, Hara M, Toyama Y, Horiuchi T, Tao K, Yasutomo K, Hamada D, Yasui N, Inoue H, Itakura M, Yamanaka H, Momohara S: Association study of TRAF1-C5 polymorphisms with susceptibility to rheumatoid arthritis and systemic lupus erythematosus in Japanese. *Ann. Rheum. Dis.* 69(2): 368-373, 2010

## 2. 学会発表（シンポジウム、招待講演を抜粋）

• 堀内孝彦: 突発性浮腫・遺伝性血管性浮腫.  
第 47 回日本成人病（生活習慣病）学会学術集会. 2013 年 1 月 12 日, 東京

• 堀内孝彦: 我が国における TRAPS (TNF 受容体関連周期性症候群) の特徴.  
第 116 回日本小児科学会学術集会. 2013 年 4 月 20 日, 広島

• 堀内孝彦: TNF 阻害薬の作用機序 共通点と相違点、そして臨床効果との関連 .  
第 22 回日本脊椎関節炎学会総会. 2012 年 9 月 29 日, 大阪

• 堀内孝彦: 全身性エリテマトーデス 病

態解明と治療の最近の進歩 .

第 27 回日本臨床リウマチ学会総会. 2012 年 11 月 24 日, 神戸

• 堀内孝彦: 全身性エリテマトーデスの診療 - 最近の進歩 - .

第 43 回日本内科学会九州支部主催生涯教育講演会. 2011 年 1 月 29 日, 福岡

• 堀内孝彦: 突発性浮腫の鑑別と治療.

第 48 回補体シンポジウム. 2011 年 9 月 3 日, 名古屋

• 堀内孝彦: 難治性炎症性疾患の画期的治療薬 - 抗 TNF 製剤の基礎と臨床 - .

第 40 回日本免疫学会学術集会. 2011 年 11 月 29 日, 千葉

• 堀内孝彦: 生物学的製剤と炎症制御 - TNF 阻害薬を中心に - .

愛媛大学プロテオ医学研究センター第 1 回学術シンポジウム. 2011 年 2 月 6 日, 松山

• 堀内孝彦: TNF とリウマチ性疾患 - その病態から治療まで - .

第 41 回九州リウマチ学会(日本リウマチ学会九州・沖縄支部学術集会). 2011 年 3 月 19 - 20 日, 宮崎

• 堀内孝彦: TNF 阻害薬の登場から 10 年たって - その現状と未来 - .

第 32 回日本炎症・再生医学会総会. 2011 年 6 月 2 日, 京都

• 堀内孝彦: 全身性エリテマトーデスの病

態解明と治療 - 最近の進歩 - .

第 55 回日本リウマチ学会総会. 2011 年 7  
月 19 日, 神戸

・堀内孝彦: 抗 TNF 製剤の作用機序 - その  
共通点と相違点 - .

第 54 回日本リウマチ学会総会. 2010 年 4  
月 22 ~ 25 日, 神戸

・堀内孝彦: 遺伝性血管性浮腫 (HAE) ガイ  
ドライン 2010.

第 14 回日本救急医学会九州地方会総会.  
2010 年 5 月 15 日, 沖縄

・堀内孝彦:

抗 TNF 製剤の作用機序 - その共通点と相  
違点そして臨床効果との関連 - .

第 31 回日本炎症・再生医学会総会. 2010  
年 8 月 6 - 7 日, 東京

・堀内孝彦: たかが浮腫とあなどることな  
き - 遺伝性血管性浮腫の基礎と臨床 - .

第 43 回日本薬剤師会学術大会. 2010 年 10  
月 10 日, 長野

2. その他の研究分担者の「研究発表」に  
ついては抜粋とした。

研究分担者 : 石ヶ坪良明

・ Ideguchi H, Suda A, Takeno M, Ueda A,  
Ohno S, Ishigatubo Y: Behcet disease:  
evolution of clinical manifestations.  
*Medicine (Baltimore)* 90(2): 125-132,  
2011

・ Ideguchi H, Suda A, Takeno M, Ueda A,  
Ohno S, Ishigatubo Y: Characterization  
of vascular involvement in Behcet's disease  
in Japan: a retrospective cohort study.  
*Clin. Exp. Rheumatol.* 29(4 Suppl 67): S47-53,  
2011

・ 石ヶ坪良明、寒川整 : 自己炎症疾患として  
のベーチェット病. *Jpn. J. Clin. Immunol.*  
34(5):408-419, 2011

・ Mizuki N, Meguro A, Ota M, Ohno  
S, Shiota T, Kawagoe T, Ito N, Kera J,  
Okada E, Yatsu K, Song YW, Lee EB,  
Kitaichi N, Namba K, Horie Y, Takeno M,  
Sugita S, Mochizuki M, Bahram S,  
Ishigatubo Y, Inoko H. Genome-wide  
association studies identify IL23R-IL12RB2  
and IL10 as Behcet's disease susceptibility  
loci. *Nat. Genet.* 42(8): 703-6, 2010

・ Takase K, Ohno S, Ideguchi H,  
Takeno M, Shirai A, Ishigatubo Y.  
Use of musculoskeletal ultrasound in  
Japan. A survey of practicing  
rheumatologist. *Mod. Rheumatol* 20(4):  
376-80, 2010

研究分担者 : 楠原浩一

・ 楠原浩一 : PFAPA 症候群. *Jpn. J. Clin.  
Immunol* 34(5): 401-407, 2011

・ Ikeda K, Yamaguchi K, Tanaka T, Mizuno  
Y, Hijikata A, Ohara O, Takada H,  
Kusuhara K, Hara T. Unique activation

status of peripheral blood mononuclear cells at acute phase of Kawasaki disease.  
*Clin.Exp.Immunol.*160(2): 246-55, 2010

研究分担者：武井修治

• Imagawa T, Takei S, Umebayashi H, Yamaguchi K, Itoh Y, Kawai T, Iwata N, Murata T, Okafuji I, Miyoshi M, Onoe Y, Kawano Y, Kinjo N, Mori M, Mozaffarian N, Kupper H, Santra S, Patel G, Kawai S, Yokota S. Efficacy, pharmacokinetics, and safety of adalimumab in pediatric patients with juvenile idiopathic arthritis in Japan.  
*Clin. Rheumatol* 31(12):713-21, 2012

• Yokota S, Imagawa T, Murata T, Tomiita M, Itoh Y, Fujikawa S, Takei S, Mori M: Guideline on the use of adalimumab for juvenile idiopathic arthritis in Japan.

*Cytokine* 58(2):287-94, 2012

• Koike T, Harigai M, Inokuma S, Ishiguro N, Ryu J, Takeuchi T, Takei S, Tanaka Y, Ito K, Yamanaka H: Postmarketing surveillance of tocilizumab for rheumatoid arthritis in Japan: interim analysis of 3881 patients.  
*Ann.Rheum.Dis* 70(12):2148-51, 2011

• Yokota S, Imagawa T, Takei S, Murata T, Tomiita M, Itoh Y, Fujikawa S, Mori M: Guidance on using tocilizumab for juvenile idiopathic arthritis. *Mod. Rheumatol.* 21 (6): 563-571, 2011

• Mori M, Takei S, Imagawa T, Imanaka H, Nerome Y, Kurosawa R, Kawano Y, Yokota S,

Sugiyama N, Yuasa H, Fletcher T, Wajdula JS: Etanercept in the treatment of disease-modifying anti-rheumatic drug (DMARD)-refractory polyarticular course juvenile idiopathic arthritis: experience from Japanese clinical trials. *Mod. Rheumatol.* 21(6):572-78, 2011

• Takei S, Hoshino T, Matsunaga K, Sakazaki Y, Sawada M, Oda H, Takenaka S, Imaoka H, Kinoshita T, Honda S, Ida H, Fukuda TA, Aizawa H: Soluble interleukin-18 receptor complex is a novel biomarker in rheumatoid arthritis. *Arthritis Res.Ther.* 13(2):R52, 2011

• 武井修治：若年性関節炎へのアプローチ . リウマチ病学テキスト . pp48-50, 編集：日本リウマチ学会生涯教育委員会、日本リウマチ財団教育研修委員会, 診断と治療社, 東京, 2010

• 武井修治：若年性特発性関節炎(JIA) . リウマチ診療の要点と盲点 . pp68-70, 監修：岩本英幸、編集：木村友厚 . 文光堂, 東京, 2010

• 武井修治：関節リウマチ(第2版) - 若年性特発性関節炎 . 日本臨床 68(増5) : 550-55, 2010

研究分担者：蓑田清次

• Minota S: Physico-chemical characteristics of TNF blockers and their effectiveness in the treatment of rheumatoid arthritis: the theoretical and real worlds. *Mod. Rheumatol* 2012 Sep 6. Epub ahead of print

- Nagashima T, Iwamoto M, Matsumoto K, Minota S: Interleukin-18 in adult-onset Still's disease:treatment target or disease activity indicator? *Intern.Med* 51(4):449, 2012
- Kamata Y,Iwamoto M,Muroi K,Minota S.Repeated local implantation of autologous peripheral blood mononuclear cells for the treatment of ischaemic digits in patients with connective tissue diseases. *Rheumatology(Oxford)* 50(5):906-10,2011
- Nagashima T,Minota S. Is polymyositis of dermatomyositis in patients with rheumatoid arthritis induced or unveiled by anti-tumor necrosis factor treatment? *Clin. Rheumatol*29(7):819-20, 2010
- Nagashima T, Minota S. Autoimmune hepatitis and adult-onset Still's disease:can they coexist? *Clin.Rheumatol*29(4):449-50, 2010
- 研究分担者：井田弘明
  - Migita K, Uehara R, Nakamura Y, Yasunami M, Tsuchiya-Suzuki A, Yazaki M, Nakamura A, Masumoto J, Yachie A, Furukawa H, Ishibashi H, Ida H, Yamazaki K, Kawakami A, Agematsu K : Familial Mediterranean fever in Japan. *Medicine(Baltimore)*91(6):337-43, 2012
  - Kawakami A, Migita K, Ida H, Yoshiura K, Arima K, Eguchi K : 自己炎症症候群 . 日本内科学会雑誌 101(9):2733-9, 2012
  - Arima K,Kinoshita A, Mishima H, Kanazawa N,Kaneko T, Mizushima T, Ichinose K, Nakamura H, Tsujino A, Kawakami A, Matsunaka M, Kasagi S, Kawano S, Kumagai S,Ohmura K,Mimori T, Hirano M,Ueno S, Tanaka K,Tanaka M, Toyoshima I, SuginoH, Yamakawa A, Tanaka K, Niikawa N, Furukawa F, MurataS, Eguchi K, Ida H, YoshiuraK: Proteasome assembly defect due to a proteasome subunit beta type8(PSMB8) mutation causes the autoinflammatory disorder, Nakajo-Nishimura syndrome. *Proc. Natl. Acad. Sci.USA.* 108(36):14914-19, 2011
  - Shimada Y, Nishida H, Nishiyama Y, Kobayashi H, Higuchi TEto Y,Ida H,Ohashi T:Proteasome inhibitors improve the function of mutant lysosomal -glucosidase in fibroblasts from Pompe disease patient carrying c546G>T mutation. *Biochem. Biophys. Res.Comun*415(2):274-8,2011
  - 井田弘明:TRAPS の病態から炎症を考える. 細胞 42(9):367-78,2010
  - 井田弘明 :自己炎症症候群. カレントテラピー 28(10):970-1,2010
  - Hida A, Imaizumi M, Sera N, Akahoshi M, Soda M, Maeda R, Ida H, Kawakami A, Eguchi K. Association of human T

lymphotropic virus type 1 with Sjogren syndrome. *Ann.Rheum. Dis* 69(11); 2056-7, 2010

研究分担者：高橋裕樹

• Takahashi H, Yamamoto M, Tabeya T, Suzuki C, Naishiro Y, Shinomura Y, Imai K : The immunobiology and clinical characteristics of IgG4 related diseases. *J. Autoimun* 39(1-2):93-6, 2012

• Takano K, Yamamoto M, Kondo A, Takahashi H, Himi T :A clinical study of olfactory dysfunction in patients with Mikulicz's disease. *Auris.Nasus.Larynx* 38(3):347-51, 2011

• Takahashi H, Yamamoto M, Suzuki C, Naishiro Y, ShinomuraY, Imai K. The birthday of a new syndrome: IgG4-related diseases constitute a clinical entity.

*Autoimmunity Rev* 9(9):591-4, 2010

研究分担者：藤井隆夫

• Nakano M, Fujii T, Hashimoto M, Yukawa N, Yoshifiji H, Ohmura K, Nakaizumi A, Mimori T : Type I interferon induces CX3CL1 (fractalkine) and CCL5 (RANTES) production in human pulmonary vascular endothelial cells.

*Clin.Exp.Immunol.*170(1): 94-100,2012

• YukawaN, Fujii T, Kondo-Ishikawa S, Yoshifiji H, Kawabata D, Nojima T, Ohmura K, Usui T, Mimori T: Correlation of

antinuclear antibody and anti-double-stranded DNA antibody with clinical response to infliximab in patients with rheumatoid arthritis: a retrospective clinical study. *Arthritis Res. Ther.*13(6): R213,2011

• Iguchi-Hashimoto M, Usui T, Yoshifiji H, Shimizu M, Kobayashi S, Ito Y, Murakami K, Shiomi A, Yukawa N, Kawabata D, Nojima T, Ohmura K, Fujii T, Mimori T: Overexpression of a minimal domain of calpastatin suppresses IL-6 production and Th17 development via reduced NF- $\kappa$ B and increased STAT5 signals. *PLoS One* 6(10):e27020,2011

• Nakashima R, Imura Y, Kobayashi S, YukawaN, Fujii T et al. The RIG-I-like receptor IFIH1/MDA5 is a dermatomyositis-specific autoantigen identified by the anti-CADM-140 antibody. *Rheumatology (Oxford)* 49(3):433-40,2010

• Sato T, Fujii T, Yokoyama T, et al. Anti-U1RNP antibodies in cerebrospinal fluid are associated with central neuropsychiatric manifestations in systemic lupus erythematosus and mixed connective tissue disease. *Arthritis Rheum* 62(12):3730-40, 2010

研究分担者：田平知子

• Iwashita Y, Fukuchi N, Waki M, Hayashi K, Tahira T : Genome-wide repression of NF- $\kappa$ B target genes by transcription factor

MIBP1 and its modulation by O-linked  
-N-acetylglucosamine(O-GlcNAc)  
transferase. *J. Biol. Chem.* 287(13):9887-900,  
2012

• Kondo H, Kusaka S, Yoshinaga A, Uchino E,  
Tawara A, Hayashi K, Tahira T: Mutations  
in the TSPAN12 gene in Japanese patients  
with familial exudative vitreoretinopathy.  
*Am. J.Ophthalmol.* 151(6):1095-100, 2011

• Kukita Y, Yahara K, Tahira T,  
Higasa K, Sonoda M, Yamamoto K,  
Kato K, Wake N, Hayashi K. A  
definitive haplotype map as determined by  
genotyping duplicated haploid genomes  
finds a predominant haplotype preference  
at copy number variation events. *Am.*  
*J.Hum. Genet.* 86(6):918-28, 2010

研究分担者：塚本浩

・塚本浩、上田尚靖、堀内孝彦：TNF  
receptor-associated periodic syndrome  
(TRAPS) における診断と治療法の進歩。  
*Jpn. J.Clin.Imunol* 34(5):361-368, 2011

・塚本浩、三苦弘喜、堀内孝彦：生物学的製  
剤の作用機序。 *Frontiers in Rheumatology&*  
*Clinical Immunology* 5(2):41-8, 2011

研究分担者：宮原寿明

・ Maeshima K, Yamaoka K, Kubo S, Nakano  
K, Iwata S, Saito K, Ohishi M, Miyahara H,  
Tanaka S, Ishii K, Yoshimatsu H, Tanaka

Y:A KAK inhibitor tofacitinib regulates  
synovitis through inhibition of IFN- and  
IL-17 production by human CD4(+)T cells.  
*Arthritis Rheum* 64(6):1790-8, 2012

G . 知的所有権の取得状況

1 . 特許取得

なし

2 . 実用新案登録

なし

3 . その他

特記事項なし